A new study shows dopamine isn’t the brain’s movement “gas pedal” after all. Instead of setting speed or strength, it quietly ...

A McGill-led study is challenging a popular theory about how dopamine drives movement, a discovery that could shift how scientists think about Parkinson's disease treatments.

Scientists have developed a groundbreaking technique enabling them to visualise tiny brain clusters believed to trigger Parkinson’s disease. Researchers hailed the breakthrough, likening it to "being ...

The world's largest-ever clinical trial of treatments to slow or stop the progression of Parkinson's disease has launched, led by researchers at UCL and Newcastle University. The £26 million project ...

New UK Biobank data reveal that falling daily step counts may flag emerging Parkinson’s years before diagnosis, offering a simple digital clue to early neurodegenerative changes. Study: Daily steps ...

In the late 1960s, scientists discovered a miracle drug for Parkinson’s disease — a simple, inexpensive dopamine-replacement pill called levodopa. It transformed the lives of millions of people.

Parkinson’s disease currently affects nearly one million Americans with no specific known cause and no cure. Treatments have come a long way over the past few decades focusing on managing symptoms and ...

Submission supported by data from the Phase 3 TEMPO program that demonstrated symptomatic improvement across the Parkinson's disease spectrum Positive results across all three Phase 3 TEMPO trials ...

A 67-year-old says a new £2,000 device, which is being studied by the NHS, has improved his sleep and allowed him to go back ...

(Beyond Pesticides, October 31, 2025) A review in Lancet Neurology provides a clear snapshot of the state of scientific understanding of Parkinson’s disease and how medicine and policy could be ...